Cure8 research brief
Understanding how different forms of programmed cell death in the gut lining contribute to barrier loss and inflammation could point to new therapeutic targets for IBD. The review also flags natural products and traditional medicines being studied as modulators of these death pathways.
Researchers studying IBD pathogenesis or drug discovery, clinicians interested in emerging mechanisms of epithelial injury in IBD, and translational scientists exploring novel therapeutics.
This is a 2026 journal review summarizing programmed cell death (PCD) pathways active in intestinal epithelial cells (IECs) in IBD — including apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis — and their regulatory mechanisms across molecular, cellular, and tissue levels.
The article surveys intervention strategies aimed at these death pathways and highlights interest in natural products and traditional Chinese medicine compounds as potential modulators.
It also discusses challenges such as heterogeneity of mechanisms and outlines directions for future research toward precise regulation of IEC PCD and therapeutic target discovery. The content provided here is grounded in the article abstract (structured content depth: abstract) and does not represent a review of the full paper.
If you want the primary research cited or specific molecular targets mentioned in the full review, consult the full article on the journal site or Europe PMC record.
This entry is a review article (abstract available). It synthesizes prior studies rather than reporting new clinical trial results; findings and proposed targets will need confirmation in experimental and clinical studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
This review outlines BEVs as a microbiome-derived, engineered nanotherapy concept that could influence gut barrier repair and immune regulation—areas directly relevant to managing IBD activity and treatment resistance.
